In RSV, Moderna's mRESVIA vaccine generated $2 million in sales during the quarter and is now approved for adults aged 60 and older in 40 countries, including approval for high-risk adults aged 18 to 59 in 31 of those countries. Despite these developments, total revenue fell 45$140 million prior-year adjustment that had increased prior-year quarter figures. Retail channels accounted for 72% of vaccinations in the fal ...